AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|
12.7 C
New York
Friday, October 23, 2026

Tag: agonist

newsFORsourcecompanycontentinformation1releasesmarket

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ --  ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for...

Ascletis’ Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building...

Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain.Following successful Phase I results...

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

-     Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.-     ASC36o, a once-weekly oral amylin receptor peptide agonist, is...

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

-     Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.-     ASC36o, a once-weekly oral amylin receptor peptide agonist, is...

Lilly’s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative...

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label...

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodiesTAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"...

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for the Treatment of Advanced Prostate Cancer; Changchun GeneScience Pharmaceutical will Commercialize in China

TAIPEI, Oct. 12, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical...

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson’s disease, as Phase II trial begins

Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026The...

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020

New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chainSite will employ more than 600 people in high-wage...

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Sheba Medical Center, which is ranked the #7 hospital in the world,...

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).

AM Rx Announces Expanded Online Access and Insurance Support for Zepbound

Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care 
Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAgonist

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers